A Charge Variant of Bevacizumab Offers Enhanced FcRn-Dependent Pharmacokinetic Half-Life and Efficacy.

Sumit K SinghDeepak KumarSaurabh NagpalSunil K DubeyAnurag Singh Rathore

Published in: Pharmaceutical research (2022)

Overall, we conclude that the mAb half-life, dosage, and efficacy of a biotherapeutic product are significantly impacted by the charge variant profile of a biotherapeutic product.

Keyphrases

solar cells
monoclonal antibody
metastatic colorectal cancer